Abstract
Characterisation of the hepatitis C virus (HCV) life cycle has enabled the development of direct-acting antiviral drugs that target different steps in the viral replication process. So far, many new antiviral compounds such as NS3/4A protease inhibitors, nucleoside and non-nucleoside polymerase inhibitors, and NS5A inhibitors have entered clinical testing.1 The approval of the first generation protease inhibitors telaprevir and boceprevir as a concomitant addition to the previous standard of care—a combination of pegylated interferon alfa (peginterferon) and weight-based ribavirin—has remarkably improved the treatment's effectiveness in patients with HCV genotype-1 infection.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
